Sean E. Brynjelsen
Net Worth
Last updated:
What is Sean E. Brynjelsen net worth?
The estimated net worth of Mr. Sean E. Brynjelsen is at least $21,789,510 as of 22 Sep 2022. He owns shares worth $16,848,000 as insider and has received compensation worth at least $4,941,510 in Eton Pharmaceuticals, Inc..
What is the salary of Sean E. Brynjelsen?
Mr. Sean E. Brynjelsen salary is $705,930 per year as Pres, Chief Executive Officer & Director in Eton Pharmaceuticals, Inc..
How old is Sean E. Brynjelsen?
Mr. Sean E. Brynjelsen is 53 years old, born in 1972.
What stocks does Sean E. Brynjelsen currently own?
As insider, Mr. Sean E. Brynjelsen owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | Pres, Chief Executive Officer & Director | 1,040,000 | $16.2 | $16,848,000 |
What does Eton Pharmaceuticals, Inc. do?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Sean E. Brynjelsen insider trading
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals key executives
Eton Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Mr. Sean E. Brynjelsen (53) Pres, Chief Executive Officer & Director
- Mr. W. Wilson Troutman CPA (71) Chief Financial Officer, Treasurer & Sec.